{"publication_id":"9ff9a2ac-5a2c-4db3-8004-dff34731a3f4","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study","doi":"10.2337/dc25-0824","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","doi":"10.1038/s41591-025-03978-z","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study","doi":"10.1007/s12325-026-03610-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials","doi":"10.1007/s12325-026-03523-5","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","doi":"10.1002/edm2.70136","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study","doi":"10.1186/s12902-025-01913-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial","doi":"10.1093/eurheartj/ehaf690","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis","doi":"10.1111/dom.70742","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly","doi":"10.2337/dc25-2041","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials","doi":"10.1111/dom.70770","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies","doi":"10.1371/journal.pmed.1005064","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","doi":"10.3389/fcvm.2024.1379189","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial","doi":"10.2196/62667","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Once-Weekly Semaglutide in Adults With Daily Cigarette Use","doi":"10.1001/jamanetworkopen.2026.14898","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial","doi":"10.1371/journal.pone.0302155","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study","doi":"10.1136/bmjopen-2024-089862","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis","doi":"10.1111/cob.70092","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials","doi":"10.1111/dom.70697","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults","doi":"10.1136/bmjopen-2023-081401","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.","doi":"10.7417/ct.2026.2083","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial","doi":"10.1111/dom.15386","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials","doi":"10.3389/fmed.2026.1764664","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Efficacy of Semaglutide S n.d.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Primary Prevention and Uterine n.d.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}